Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Onyx Pharmaceuticals, Inc. (ONXX), Pharmacyclics, Inc. (PCYC): Will This Biotech Acquisition Buzz Lead to More Buyouts?

Page 1 of 2

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is trading higher after rejecting a takeover bid. As other stocks in its sector also trade higher in sympathy, will any of them become takeover targets, too?

What’s Creating The Buzz

The analysts, bloggers, and columnists were out in full force last Monday morning to assess the true “worth” of Onyx. The company markets cancer drugs Nexavar and Stivarga with Bayer, and solely develops Kyprolis. According to most analysts, Onyx has the potential to produce peak sales between $4 billion and $4.5 billion, and would add value to any company developing cancer therapeutics.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is trading higher by 51% at $131, now that many investors expect a $150 per share bid after the company rejected a $120 offer from Amgen. At $150, Onyx would be valued at $11 billion for its $4 billion-$4.5 billion in peak sales potential.

While I have little doubt that Amgen, Bayer, or one of many other Big Pharma companies will acquire Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), there are countless stocks rallying in sympathy. Investors apparently believe that they, too, are acquisition targets. Here are two that I believe may also be acquired, each with a strong presence in oncology.

High Margins and Blockbuster Sales Make This Company a Target

Pharmacyclics, Inc. (NASDAQ:PCYC) is a market leader in the development of chronic lymphocytic leukemia. Its lead product, Ibrutinub, is being tested in seven different clinical trials, and is estimated to produce sales north of $3.5 billion by 2019.

Like Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and its partnership with Bayer, Pharmacyclics is partnered with Johnson & Johnson in a deal to develop Ibrutinub that could be worth $957 million. Pharmacyclics will be responsible for 40% of the product launch costs and receive 50% of the revenue — in short, it got a very good deal.

If $3.5 billion in peak Ibrutinub sales are reached, Pharmacyclics, Inc. (NASDAQ:PCYC) should earn $1.75 billion. Most importantly, analysts project that because of the company’s low costs, a profit margin of 40% is possible for Pharmacyclics. Therefore, Pharmacyclics could earn $700 million in annual profits, and it should have many years of exclusivity due to the diversified development of the drug. This makes Pharmacyclics, Inc. (NASDAQ:PCYC) very attractive.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!